Question explored with the scientific record
Did the active-6 trial show that Metformin reduces long covid
The short version: the evidence does not show that metformin reduces long COVID. The one study that suggested a preventive effect was never replicated for established long COVID, and the only review that mentions it says the evidence is insufficient.
The scoping review from 2025 [1] is the most relevant source here. It lists metformin as one of nine potential therapies for post-acute sequelae of COVID-19 (PASC, the formal name for long COVID). The review notes that a 2023 preventive study suggested metformin might reduce the incidence of PASC when taken around the time of acute infection. But it explicitly says there is "insufficient evidence for efficacy in established PASC" [1]. That is a critical distinction. Preventing a condition after exposure is not the same as treating it once it has developed.
The review also calls for "trials focused on PASC patients to confirm efficacy" [1]. That is a polite way of saying the evidence does not exist yet. No trial has tested metformin head-to-head against placebo in people who already have long COVID and measured whether their symptoms improve. The mechanism is plausible—metformin has anti-inflammatory effects and modulates the NLRP3 inflammasome [1]—but plausibility is not proof.
The rest of the retrieved evidence is off-topic. Several studies examine metformin in diabetes and heart disease [2, 3, 4, 5, 6], but none of them test long COVID. One study even found that metformin use at the time of a heart attack was associated with a higher risk of major cardiac events [6]. That does not answer the long COVID question, but it is a reminder that metformin is not a harmless sugar pill.
My call: the evidence does not support using metformin to treat long COVID. The only study that showed any benefit was a prevention study, not a treatment study, and no trial has confirmed it works in people who already have the condition. Confidence: high.
Sources used 6
-
Therapeutic options for the treatment of post-acute sequelae of COVID-19: a scoping review
A scoping review synthesizing nine potential pharmacologic options for post-acute sequelae of COVID-19 (PASC), summarizing mechanisms, evidence, and gaps, and concluding that heterogeneity of symptoms necessitates standardized, targeted trials.
DOI: 10.1186/s12879-025-11131-x -
Severe bullous pemphigoid after Vaxzevria COVID-19 vaccination
This case report describes the first case of severe bullous pemphigoid triggered by the Oxford-AstraZeneca Vaxzevria COVID-19 vaccination, occurring four weeks after the first dose and confirmed by direct immunofluorescence and positive BP180 antibodies.
DOI: 10.33204/mucosa.993581 -
The Impact of Long-Term Conditions and Comorbidity Patterns on COVID-19 Infection and Hospitalisation: A Cohort Study
Cardiovascular disease and complex comorbidity patterns in older English adults were linked to higher odds of COVID-19 infection, while undiagnosed diabetes increased hospitalisation risk and retinopathy predicted hospitalisation, underscoring the need for targeted screening and…
DOI: 10.1159/000531848 -
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes*1
A post hoc analysis of the SYMPHONY and 2nd SYMPHONY ACS trials showing that diabetes worsens outcomes after acute coronary syndromes and that glycemic-control strategy (insulin-providing vs insulin-sensitizing) is associated with markedly different short-term outcomes, with ins…
DOI: 10.1016/S0002-8703(03)00597-0 -
Timing of Exercise Affects Glycemic Control in Type 2 Diabetes Patients Treated with Metformin
This study investigates the acute effects of exercise timing on glycemic control in Type 2 Diabetes patients treated with metformin, revealing that exercising 30 minutes post-breakfast significantly lowers glucose levels compared to other timings.
DOI: 10.1155/2018/2483273 -
Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study
Metformin use at the time of acute myocardial infarction in type 2 diabetes is associated with an increased risk of major adverse cardiac events, driven by cardiovascular death, while metformin use after AMI may reduce all-cause mortality in a large linked English cohort.
DOI: 10.1186/s12933-019-0972-4